API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/delhi-high-court-seeks-response-from-govt-nppa-on-glenmarks-plea/articleshow/109169586.cms
https://www.prnewswire.com/in/news-releases/glenmark-becomes-the-first-company-to-launch-remogliflozin-vildagliptin-fixed-dose-combination-at-an-affordable-price-for-adults-with-type-2-diabetes-in-india-821947177.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-launches-cut-price-copies-of-astrazenecas-patented-anti-diabetes-drug/articleshow/75022602.cms
https://health.economictimes.indiatimes.com/news/pharma/mankind-pharma-signs-up-with-glenmark-pharmaceuticals-for-co-marketing-of-remogliflozin-etabonate-in-india/72936643
https://endpts.com/glenmark-launches-remogliflozin-combo-in-india-genecentric-therapeutics-buys-select-immunogenomics/
https://www.business-standard.com/article/pti-stories/glenmark-torrent-pharma-ink-licensing-pact-to-co-market-diabetes-drug-in-india-119071100312_1.html
https://www.thepharmaletter.com/article/glenmark-and-torrent-licensing-deal-for-remogliflozin-etabonate-in-india
https://www.moneycontrol.com/news/business/companies/glenmark-launches-cheaper-sglt2-inhibitor-class-of-anti-diabetes-drug-in-india-3913361.html